Atezolizumab Monotherapy for Metastatic Urothelial Carcinoma: Final Analysis from the Phase II IMvigor210 Trial

Overview

Journal ESMO Open

Publisher Elsevier

Specialty Oncology

Date 2024 Dec 6

PMID 39642637

Authors

J E Rosenberg

M D Galsky

T Powles

D P Petrylak

J Bellmunt

Y Loriot

A Necchi

J Hoffman-Censits

J L Perez-Gracia

M S van der Heijden

R Dreicer

I Duran

D Castellano

A Drakaki

M Retz

S S Sridhar

P Grivas

E Y Yu

P H ODonnell

H A Burris

S Mariathasan

Y Shi

E Goluboff

D Bajorin

Affiliations

Soon will be listed here.

Abstract

Background: The IMvigor210 trial demonstrated clinical benefit and manageable toxicity with atezolizumab monotherapy [anti-programmed death-ligand 1 (PD-L1)] in patients with metastatic urothelial carcinoma (UC) in primary analyses. Final efficacy and safety results after long-term follow-up are reported.

Patients And Methods: This phase II single-arm trial of atezolizumab monotherapy in patients with advanced UC included two cohorts: untreated patients ineligible for cisplatin-based chemotherapy (cohort 1; n = 119) and those previously treated with platinum-based chemotherapy (cohort 2; n = 310). Atezolizumab was administered i.v. (1200 mg every 21 days) until progression or unacceptable toxicity. Primary endpoints were independent review facility-assessed confirmed objective response rate (ORR) per RECIST 1.1 in cohort 1 and independent review facility-assessed ORR per RECIST 1.1 and investigator-assessed modified (m)RECIST in cohort 2. Overall survival (OS), efficacy by PD-L1 status, and safety were also assessed.

Results: At data cut-off (1 June 2023), the median survival follow-up was 96.4 months (range, 0.2-103.4 months) in cohort 1 and 46.2 months [0.2 (censored)-54.9 months] in cohort 2. In cohort 1, the ORR [95% confidence interval (CI)] was 23.5% (16.2% to 32.2%) in all patients and 28.1% (13.8% to 46.8%) in the PD-L1 tumor-infiltrating immune cell (IC)2/3 subgroup. Median OS (95% CI) was 16.3 months (10.4-24.5 months) overall and 12.3 months (6.0-49.8 months) in the PD-L1 IC2/3 subgroup. In cohort 2, the ORR (95% CI) was 16.5% (12.5% to 21.1%) per RECIST 1.1 and 19.7% (95% CI 15.4% to 24.6%) per mRECIST in all patients and 27.0% (18.6% to 36.8%) and 28.0% (19.5% to 37.9%), respectively, in the PD-L1 IC2/3 subgroup. Median OS (95% CI) was 7.9 months (6.7-9.3 months) in all patients and 11.9 months (9.0-22.8 months) in the IC2/3 subgroup. Treatment-related grade 3/4 adverse events occurred in 21.8% (cohort 1) and 18.7% (cohort 2); one treatment-related death occurred in cohort 1.

Conclusions: With long-term follow-up, atezolizumab monotherapy demonstrated clinically meaningful efficacy with durable responses in a subset of patients with metastatic UC; there were no new safety signals.

References

Powles T, Park S, Caserta C, Valderrama B, Gurney H, Ullen A . Avelumab First-Line Maintenance for Advanced Urothelial Carcinoma: Results From the JAVELIN Bladder 100 Trial After ≥2 Years of Follow-Up. J Clin Oncol. 2023; 41(19):3486-3492. PMC: 10306435. DOI: 10.1200/JCO.22.01792. View

Grivas P, Pouessel D, Park C, Barthelemy P, Bupathi M, Petrylak D . Sacituzumab Govitecan in Combination With Pembrolizumab for Patients With Metastatic Urothelial Cancer That Progressed After Platinum-Based Chemotherapy: TROPHY-U-01 Cohort 3. J Clin Oncol. 2024; 42(12):1415-1425. PMC: 11095901. DOI: 10.1200/JCO.22.02835. View

Vennapusa B, Baker B, Kowanetz M, Boone J, Menzl I, Bruey J . Development of a PD-L1 Complementary Diagnostic Immunohistochemistry Assay (SP142) for Atezolizumab. Appl Immunohistochem Mol Morphol. 2018; 27(2):92-100. PMC: 6369970. DOI: 10.1097/PAI.0000000000000594. View

Jackson-Spence F, Toms C, OMahony L, Choy J, Flanders L, Szabados B . IMvigor011: a study of adjuvant atezolizumab in patients with high-risk MIBC who are ctDNA+ post-surgery. Future Oncol. 2023; 19(7):509-515. DOI: 10.2217/fon-2022-0868. View

van der Heijden M, Sonpavde G, Powles T, Necchi A, Burotto M, Schenker M . Nivolumab plus Gemcitabine-Cisplatin in Advanced Urothelial Carcinoma. N Engl J Med. 2023; 389(19):1778-1789. DOI: 10.1056/NEJMoa2309863. View

Powles T, Bellmunt J, Comperat E, De Santis M, Huddart R, Loriot Y . Bladder cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2021; 33(3):244-258. DOI: 10.1016/j.annonc.2021.11.012. View

Bellmunt J, de Wit R, Vaughn D, Fradet Y, Lee J, Fong L . Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma. N Engl J Med. 2017; 376(11):1015-1026. PMC: 5635424. DOI: 10.1056/NEJMoa1613683. View

Powles T, Eder J, Fine G, Braiteh F, Loriot Y, Cruz C . MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature. 2014; 515(7528):558-62. DOI: 10.1038/nature13904. View

Powles T, Catto J, Galsky M, Al-Ahmadie H, Meeks J, Nishiyama H . Perioperative Durvalumab with Neoadjuvant Chemotherapy in Operable Bladder Cancer. N Engl J Med. 2024; 391(19):1773-1786. DOI: 10.1056/NEJMoa2408154. View

10.

Rosenberg J, Hoffman-Censits J, Powles T, van der Heijden M, Balar A, Necchi A . Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet. 2016; 387(10031):1909-20. PMC: 5480242. DOI: 10.1016/S0140-6736(16)00561-4. View

11.

Powles T, Duran I, van der Heijden M, Loriot Y, Vogelzang N, De Giorgi U . Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial. Lancet. 2017; 391(10122):748-757. DOI: 10.1016/S0140-6736(17)33297-X. View

12.

Petrylak D, Powles T, Bellmunt J, Braiteh F, Loriot Y, Morales-Barrera R . Atezolizumab (MPDL3280A) Monotherapy for Patients With Metastatic Urothelial Cancer: Long-term Outcomes From a Phase 1 Study. JAMA Oncol. 2018; 4(4):537-544. PMC: 5885219. DOI: 10.1001/jamaoncol.2017.5440. View

13.

Powles T, Park S, Voog E, Caserta C, Valderrama B, Gurney H . Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma. N Engl J Med. 2020; 383(13):1218-1230. DOI: 10.1056/NEJMoa2002788. View

14.

Balar A, Galsky M, Rosenberg J, Powles T, Petrylak D, Bellmunt J . Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial. Lancet. 2016; 389(10064):67-76. PMC: 5568632. DOI: 10.1016/S0140-6736(16)32455-2. View

15.

Bajorin D, Witjes J, Gschwend J, Schenker M, Valderrama B, Tomita Y . Adjuvant Nivolumab versus Placebo in Muscle-Invasive Urothelial Carcinoma. N Engl J Med. 2021; 384(22):2102-2114. PMC: 8215888. DOI: 10.1056/NEJMoa2034442. View

16.

Bamias A, Davis I, Galsky M, Arranz J, Kikuchi E, Grande E . Atezolizumab monotherapy versus chemotherapy in untreated locally advanced or metastatic urothelial carcinoma (IMvigor130): final overall survival analysis from a randomised, controlled, phase 3 study. Lancet Oncol. 2023; 25(1):46-61. DOI: 10.1016/S1470-2045(23)00539-9. View

17.

Powles T, Valderrama B, Gupta S, Bedke J, Kikuchi E, Hoffman-Censits J . Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer. N Engl J Med. 2024; 390(10):875-888. DOI: 10.1056/NEJMoa2312117. View